Lv5
1220 积分 2023-04-12 加入
Efficacy and Safety of Switching to Dolutegravir/Lamivudine in Virologically Suppressed People Living with HIV-1 Aged Over 65 Years
1个月前
已完结
Efficacy and Safety of Dual Therapy With Dolutegravir/Lamivudine in Treatment-naive Persons With CD4 Counts <200/mm3: 48-Week Results of the DOLCE
1个月前
已完结
Metabolic outcomes of bictegravir/emtricitabine/tenofovir alafenamide versus dolutegravir/lamivudine in treatment-naïve people living with HIV: a 48-week retrospective study
1个月前
已完结
Metabolic outcomes of bictegravir/emtricitabine/tenofovir alafenamide versus dolutegravir/lamivudine in treatment-naïve people living with HIV: a 48-week retrospective study
1个月前
已关闭
Comparing the long-term effectiveness and safety of dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir alafenamide fumarate as first-line regimens: a real life multicentre cohort
1个月前
已完结
Comparative analysis of lipid profile changes in treatment-naïve people living with HIV on INSTI-based single-tablet regimens, BIC/FTC/TAF and DTG/3TC: real-world evidence from South Korea
1个月前
已完结
Metabolic Complications After Initiating BIC/FTC/TAF Versus DTG + 3TC in Antiretroviral-therapy-naive Adults With HIV: A Multicenter Prospective Cohort Study
1个月前
已完结
Changes in cardiovascular and metabolic risk scores after switching to DOR/3TC/TDF, DTG/3TC or BIC/FTC/TAF: results from a multicenter Italian cohort
1个月前
已完结
Perez-Valero I, et al. Int J Antimicrob Agents. 2026 Apr 27;67(8):107825
1个月前
已完结
Dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir alafenamide fumarate: Real-world assessment of effectiveness and weight Gain in naïve people living with HIV of Asian OrigiN (DRAGON)
1个月前
已完结
皖公网安备34019202002308
